Drug Profile
ABN 912
Alternative Names: ABN912; Anti-MCP-1 monoclonal antibodyLatest Information Update: 16 Jul 2010
Price :
$50
*
At a glance
- Originator Novartis
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2010 Discontinued - Phase-I for Asthma in USA (unspecified route)
- 16 Jul 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in USA (IV-infusion)
- 28 Oct 2004 Data presented at the 68th Annual Scientific Meeting of the American College of Rheumatology and the 39th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2004) have been added to the adverse events and Rheumatic disease pharmacodynamics sections